Printer Friendly

AMSCO INTERNATIONAL SAYS THIRD QUARTER EARNINGS WILL LIKELY BE LOWER THAN EXPECTED

 PITTSBURGH, Sept. 9 /PRNewswire/ -- AMSCO International, Inc. (NYSE: ASZ) today announced that it is unlikely to meet securities analysts' estimates of earnings for the third quarter of 1993.
 Analysts' estimates of fully diluted earnings per share range from $.10 to $.12 compared to $.23 for the third quarter a year ago.
 "Sales for the two months of July and August were slightly below levels for the comparable period last year," said David A. Nelson, chairman, president and chief executive officer. Given the sales performance to date in the third quarter coupled with the expectation of continued sluggishness, near-term results could be significantly below the range of forecasts by analysts."
 The company attributes the difficult sales environment to current health care market trends and related implications for medical equipment purchases. This environment makes it very difficult to predict the depth and duration of the business pace slowdown on AMSCO, Nelson said, as customers continue to be hesitant to commit to equipment purchases at this time.
 He added, however, that the company will continue to act to reduce costs and expenses where possible, while continuing to invest in growth opportunities.
 AMSCO International, Inc. is a leading provider of infection control, decontamination and surgical products and services to health care, scientific and industrial customers.
 -0- 9/9/93
 /CONTACT: Anthony Lacenere, vice president-financial affairs, of AMSCO, 412-338-6519/
 (ASZ)


CO: AMSCO International ST: Pennsylvania IN: MTC SU: ERP

KC -- PG001 -- 0131 09/09/93 08:46 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 9, 1993
Words:243
Previous Article:OATRIM RECEIVES 1993 "R&D 100" AWARD FOR TECHNOLOGICAL SIGNIFICANCE
Next Article:BRISTOL-MYERS SQUIBB, AXION PHARMACEUTICALS FORM JOINT VENTURE; CANCER DRUG DISTRIBUTION NETWORK ADDRESSES CRITICAL COST-CONTAINMENT NEEDS
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters